Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

More articles from Breast and Lung Cancer

  • You have access
    Tumor targeted drug delivery with hollow mesoporous silica nanoparticles
    Feng Chen, Hao Hong, Sixiang Shi, Hector Valdovinos, Todd Barnhart and Weibo Cai
    Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 547;
  • You have access
    (4S)-4-(3-[18F]fluoropropyl)-L-glutamate uptake correlates with cancer stem cell markers in cancer patients
    Hyo Sang Lee, Yangsoon Park, Sun Young Chae, Chain-Min Choi, Sung-Bae Kim, Norman Koglin, Andrew Stephens, Ludger Dinkelborg and Dae Hyuk Moon
    Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 548;
  • You have access
    Limitations of [18F]fluorothymidine as a proliferation biomarker in a preclinical model of breast cancer: Role of sex-dependent differences in tissue biodistribution
    Szeman Chan, Kooresh Shoghi, Carmen Dence, John Katzenellenbogen and Amy Fowler
    Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 549;
  • You have access
    Development of a HER3 PET probe for breast cancer imaging
    Eric Wehrenberg-Klee, N. Selcan Turker, Bryan Chang, Pedram Heidari and Umar Mahmood
    Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 550;
  • You have access
    In vivo enrichment of cancer stem cells in histone deacetylase inhibitor resistant xenograft of lung cancer in mouse model
    Wei-Ying Kuo, Luen Hwu, Chun-Yi Wu, Hsin-Ell Wang and Ren-Shyan Liu
    Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 546;
  • You have access
    PET 18F-FDG and SPECT 111In-cetuximab-F(ab′)2 for early response monitoring after radiotherapy in HNSCC xenografts
    Laura van Dijk, Johan Bussink, Gerben Franssen and Otto Boerman
    Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 545;
  • You have access
    PET determination of specific uptake of [11C]-erlotinib by different tumor types expressing EGFR, in vivo through kinetic modeling
    Joseph Petrulli, Jenna Sullivan, Ming-Qiang Zheng, Yiyun Huang, Joseph Contessa and Evan Morris
    Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 544;
SNMMI

© 2025 SNMMI

Powered by HighWire